Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma

被引:18
|
作者
Huang, Jing Li [1 ]
Kizy, Scott [1 ]
Marmor, Schelomo [1 ]
Altman, Ariella [1 ]
Blaes, Anne [2 ]
Beckwith, Heather [2 ]
Tuttle, Todd M. [1 ]
Hui, Jane Yuet Ching [1 ]
机构
[1] Univ Minnesota, Dept Surg, Mayo Mail Code 195,420 Delaware St SE, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Div Hematol Oncol & Transplantat, Mayo Mail Code 480,420 Delaware St SE, Minneapolis, MN 55455 USA
关键词
Breast cancer; 21-Gene recurrence score; Oncotype DX; Grade; Progesterone receptor; ENDOCRINE THERAPY; HISTOLOGIC GRADE; GENE-EXPRESSION; CANCER PATIENTS; ASSAY; ESTROGEN; IMPACT; CHEMOTHERAPY; VALIDATION; EQUATIONS;
D O I
10.1007/s10549-018-4955-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe 21-gene recurrence score (RS) assay is increasingly utilized to predict the risk of recurrence in early stage estrogen receptor (ER)-positive breast cancer. We hypothesize that tumor grade and progesterone receptor (PR) status predict RS categorization.MethodsWe identified women between the ages of 18 and 74years with stage I or II, ER-positive, invasive carcinoma of the breast from the Surveillance Epidemiology End-Results database from 2010 to 2013. Multivariable logistic regression was performed to determine factors associated with high-risk RS.ResultsWe identified 42,530 patients that met inclusion criteria. Multivariable logistic regression demonstrated that grade I tumors [OR (odds ratio) 0.33, 95% CI (confidence interval) 0.31-0.37] and PR positive (PR+) status (OR 0.16, 95% CI 0.15-0.17) were significantly less likely to be associated with high-risk RS. Of patients with grade I PR+tumors, 1% was in the high-risk group by the traditional cutoffs and 4% was in the high-risk group by the TAILORx cutoffs. The percentage of patients with high-risk RS remained low for grade I PR+tumors regardless of age, race, tumor size, and lymph node status.ConclusionsWe found that grade I PR+tumors are associated a<5% probability of having high-risk RS regardless of other patient demographic or pathologic factors. This suggests that the histologic factors of grade and PR status should be taken into consideration before ordering the 21-gene recurrence score assay.
引用
收藏
页码:671 / 677
页数:7
相关论文
共 50 条
  • [1] Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma
    Jing Li Huang
    Scott Kizy
    Schelomo Marmor
    Ariella Altman
    Anne Blaes
    Heather Beckwith
    Todd M. Tuttle
    Jane Yuet Ching Hui
    Breast Cancer Research and Treatment, 2018, 172 : 671 - 677
  • [2] Progesterone receptor status and tumor grade predict the 21-gene recurrence score of invasive lobular breast cancer
    Wu, San-Gang
    Zhang, Wen-Wen
    Wang, Jun
    Lian, Chen-Lu
    Sun, Jia-Yuan
    Chen, Yonq-Xionq
    He, Zhen-Yu
    BIOMARKERS IN MEDICINE, 2019, 13 (12) : 1005 - 1012
  • [3] Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast
    Scott Kizy
    Jing Li Huang
    Schelomo Marmor
    Todd M. Tuttle
    Jane Yuet Ching Hui
    Breast Cancer Research and Treatment, 2017, 165 : 757 - 763
  • [4] Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast
    Kizy, Scott
    Huang, Jing Li
    Marmor, Schelomo
    Tuttle, Todd M.
    Hui, Jane Yuet Ching
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (03) : 757 - 763
  • [5] Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer
    Montemurro, Filippo
    Marchio, Caterina
    Sapino, Anna
    JAMA ONCOLOGY, 2020, 6 (04) : 584 - +
  • [6] Is there a role for 21-gene recurrence score in mucinous carcinoma of breast?
    Yap, Kelly Khai Li
    Koc, Melissa
    Lu, Janice M.
    Spicer, Darcy V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
    Ma, Sung Jun
    Gill, Jasmin
    Yendamuri, Keerti
    Chatterjee, Udit
    Waldman, Olivia
    Dunne-Jaffe, Cynthia
    Fekrmandi, Fatemeh
    Shekher, Rohil
    Iovoli, Austin
    Yao, Song
    Oladeru, Oluwadamilola T.
    Singh, Anurag K.
    BMC CANCER, 2023, 23 (01)
  • [8] Tumor grade, Ki 67%, and relantionship with the 21-gene recurrence score assay in early breast cancer tumors.
    Bonta, Ioana
    Bonta, Dacian
    Blanchard, Rita A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
    Sung Jun Ma
    Jasmin Gill
    Keerti Yendamuri
    Udit Chatterjee
    Olivia Waldman
    Cynthia Dunne-Jaffe
    Fatemeh Fekrmandi
    Rohil Shekher
    Austin Iovoli
    Song Yao
    Oluwadamilola T. Oladeru
    Anurag K. Singh
    BMC Cancer, 23
  • [10] Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer Reply
    Sparano, Joseph A.
    JAMA ONCOLOGY, 2020, 6 (04) : 586 - 586